Pfizer's dividend yield 6.7% is concerning, but the dividend is solid
Pfizer's dividend yield appears high at 6.7%. The article assesses the dividend story as stronger in terms of the company's ability to pay dividends and its cash flow. Dividend sustainability and earnings and cash flow need to be checked.
Pfizer's dividend yield based on its share price reached 6.7%. The yield has risen largely because of the decline in the share price. The company is currently continuing to pay its dividend.
The assessment explains that dividends should be evaluated based on the structure of cash flow and earnings rather than as a simple figure. Based on adjusted earnings and cash flow, it is difficult to assert that the dividend is immediately at risk. However, it notes that revenue volatility in certain businesses should be monitored.
The company's past dividend history and level of cash holdings are presented as key factors in assessing whether the dividend can be maintained. It said the cash-generation ability supporting the dividend and quarterly earnings trends should be reviewed. Interpretation is needed when the yield surges due to short-term share-price volatility.
The article states that dividends and capital allocation policies should be examined together. Capital allocation activity beyond dividends, such as share buybacks, affects assessments of dividend sustainability. It recommends that investors review company announcements and quarterly results.
In conclusion, a dividend yield of 6.7% may be viewed as a warning sign for investors, but the assessment is that the story is not simple when the underlying dividend metrics are considered. Assessing dividend sustainability requires checking future earnings and cash flow, as well as changes in the company's capital allocation policy.
Sources: Yahoo Finance
Bullstory synthesized this report from the linked sources. AI may have assisted the writing process. Check the original reports for factual confirmation.